Adult Cardiology Department, Gottsegen National Cardiovascular Center, Budapest, Hungary.
Pediatric Cardiology Department, Gottsegen National Cardiovascular Center, Budapest, Hungary.
Clin Cardiol. 2023 Aug;46(8):942-949. doi: 10.1002/clc.24072. Epub 2023 Jul 5.
Catheter ablation is a rarely used procedure to treat arrhythmias during pregnancy.
In the case of maternal arrhythmia during pregnancy, zero-fluoroscopic catheter ablation is preferable to medical treatment.
Between April 2014 and September 2021, we examined the demographic data, procedural parameters, and fetal and maternal outcomes in pregnant women undergoing ablation at the Gottsegen National Cardiovascular Center and University of Pécs Medical School, Heart Institute.
Fourteen procedures (14 electrophysiological studies [EPS], 13 ablations) performed on 13 pregnant women (age 30.3 ± 5.2 years, primipara n = 6) were studied. During EPS, 12 patients had inducible arrhythmias. Atrial tachycardia was confirmed in three, atrioventricular re-entry tachycardia via manifest accessory pathway (AP) in three, and via concealed AP in one case. Atrioventricular nodal re-entry tachycardia was confirmed in three and sustained monomorphic ventricular tachycardia in two cases. Eleven radiofrequency ablation (84.6%) and two cryoablation (15.4%) were performed. The electroanatomical mapping system was used in all cases. Transseptal puncture was performed in two cases (15.4%) due to left lateral APs. The mean procedure time was 76.0±33.0 minutes. All procedures were performed without fluoroscopy. No complications occurred. During the follow-up, arrhythmia-free survival was achieved in all cases, but in two patients, we used antiarrhythmic drugs (AADs) to achieve it. APGAR score was within the normal range in all cases [median (interquartile range), 9.0/10.0 (9.0-10.0/9.3-10.0)].
Zero-fluoroscopic catheter ablation was an effective and safe treatment option for our 13 pregnant patients. Catheter ablation may have less side effects on fetal development than the use of AADs during pregnancy.
导管消融术是一种很少用于治疗妊娠期间心律失常的方法。
在妊娠期间母体发生心律失常的情况下,零射线导管消融术优于药物治疗。
在 2014 年 4 月至 2021 年 9 月期间,我们检查了在戈特塞根国家心血管中心和佩奇大学医学院心脏研究所进行消融术的孕妇的人口统计学数据、程序参数以及胎儿和母体结局。
对 13 名孕妇(年龄 30.3±5.2 岁,初产妇 n=6)进行了 14 次手术(14 次电生理研究[EPS],13 次消融术)。在 EPS 期间,12 名患者可诱发出心律失常。其中 3 例确诊为房性心动过速,3 例显性旁路(AP)证实房室折返性心动过速,1 例隐匿性 AP。3 例确诊为房室结折返性心动过速,2 例持续性单形性室性心动过速。11 例行射频消融术(84.6%),2 例行冷冻消融术(15.4%)。所有病例均使用电解剖标测系统。由于左侧侧 AP,2 例患者进行了经房间隔穿刺(15.4%)。平均手术时间为 76.0±33.0 分钟。所有手术均无射线透视下完成。未发生并发症。随访期间,所有患者均无心律失常生存,但有 2 例患者使用抗心律失常药物(AADs)达到该结果。所有病例的 APGAR 评分均在正常范围内[中位数(四分位距),9.0/10.0(9.0-10.0/9.3-10.0)]。
对于我们的 13 名孕妇患者,零射线导管消融术是一种有效且安全的治疗选择。与妊娠期间使用 AADs 相比,导管消融术对胎儿发育的副作用可能更小。